JonesResearch Starts Coverage on Atai Beckley & Mind Medicine with Buy Ratings
JonesResearch gives Buy ratings to Atai Beckley and Mind Medicine, highlighting potential in psychedelic drug development for depression and anxiety.
/ 2 items
JonesResearch gives Buy ratings to Atai Beckley and Mind Medicine, highlighting potential in psychedelic drug development for depression and anxiety.
Needham initiates Buy rating on Mind Medicine with $28 target, citing strong Phase 3 potential for MM120 treatment and $2.5B+ revenue opportunity in $12B market.